Is immunotherapy the next best option for a patient with metastatic translocation-associated renal cell carcinoma (TFEB rearrangement) after progression on 1st line sunitinib and 2nd line everolimus/lenvatinib?
Mixed opinions about efficacy of IO therapy in this subtype.
Thank you!